Celldex Therapeutics (NASDAQ:CLDX) Stock Price Up 8.2%

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) traded up 8.2% on Tuesday . The stock traded as high as $39.49 and last traded at $39.31. 630,429 shares changed hands during trading, a decline of 19% from the average session volume of 779,803 shares. The stock had previously closed at $36.34.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on CLDX. Stifel Nicolaus assumed coverage on shares of Celldex Therapeutics in a research note on Tuesday, June 18th. They issued a “buy” rating and a $58.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research report on Tuesday, June 18th. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, July 16th. Finally, Wolfe Research initiated coverage on shares of Celldex Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $51.00 price target on the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $62.17.

Celldex Therapeutics Price Performance

The company’s 50 day moving average price is $36.48 and its two-hundred day moving average price is $39.14.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The business had revenue of $0.16 million for the quarter, compared to analyst estimates of $1.30 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. As a group, research analysts anticipate that Celldex Therapeutics, Inc. will post -2.39 EPS for the current year.

Insider Buying and Selling

In other Celldex Therapeutics news, CFO Samuel Bates Martin sold 35,000 shares of the firm’s stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $34.05, for a total value of $1,191,750.00. Following the completion of the sale, the chief financial officer now directly owns 25,128 shares of the company’s stock, valued at approximately $855,608.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, SVP Diane C. Young sold 45,000 shares of Celldex Therapeutics stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $35.26, for a total transaction of $1,586,700.00. Following the sale, the senior vice president now owns 2,115 shares of the company’s stock, valued at approximately $74,574.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Samuel Bates Martin sold 35,000 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $34.05, for a total value of $1,191,750.00. Following the completion of the transaction, the chief financial officer now owns 25,128 shares of the company’s stock, valued at $855,608.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 266,332 shares of company stock worth $9,155,821. 3.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Celldex Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLDX. Fisher Asset Management LLC increased its position in shares of Celldex Therapeutics by 4.6% during the 4th quarter. Fisher Asset Management LLC now owns 21,492 shares of the biopharmaceutical company’s stock worth $852,000 after purchasing an additional 954 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in Celldex Therapeutics by 26.4% during the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after buying an additional 955 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Celldex Therapeutics by 3.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,258 shares of the biopharmaceutical company’s stock valued at $1,041,000 after acquiring an additional 962 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Celldex Therapeutics by 10.0% in the 1st quarter. Principal Financial Group Inc. now owns 13,153 shares of the biopharmaceutical company’s stock valued at $552,000 after acquiring an additional 1,194 shares during the period. Finally, Strs Ohio raised its stake in shares of Celldex Therapeutics by 92.9% in the 4th quarter. Strs Ohio now owns 2,700 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 1,300 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.